Decitabine/cedazuridine received approval in the USA and Canada for treating MDS and chronic myelomonocytic leukemia [224]. The next-generation DNMT inhibitor guadecitabine is an investigational drug for treating MDS, AML and some solid tumors [225]. This evidence concerns the gene DNMT1 and acute myeloid leukemia.